$3.01
1.17% day before yesterday
Nasdaq, Jun 28, 10:00 pm CET
ISIN
US88032L2097
Symbol
TENX

Tenax Therapeutics, Inc. Share price

$3.01
-0.49 13.86% 1M
-23.39 88.58% 6M
-18.95 86.28% YTD
-20.81 87.35% 1Y
-3,548.99 99.92% 3Y
-2,204.99 99.86% 5Y
-130,556.99 100.00% 10Y
Nasdaq, Closing price Fri, Jun 28 2024
ISIN
US88032L2097
Symbol
TENX
Sector

Key figures

Market capitalization $5.90m
Enterprise Value $-6.24m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.67
P/B ratio (TTM) P/B ratio 0.48
Turnover (TTM) Turnover $0.00
EBIT (operating result TTM) EBIT $-10.60m
Free cash flow (TTM) Free cash flow $-9.34m
Cash position $12.55m
EPS (TTM) EPS $-24.54
P/E ratio expected negative
Short interest 0.51%
Show more

Is Tenax Therapeutics, Inc. a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Tenax Therapeutics, Inc. Share analysis

Unlock scores for free

Analyst opinions

1 Analyst has issued a forecast Tenax Therapeutics, Inc.:

1x Buy
100%

Analyst opinions

1 Analyst has issued a forecast Tenax Therapeutics, Inc.:

Buy
100%

Financial data from Tenax Therapeutics, Inc.

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
- -
-
100%
- Direct costs 0.01 0.01
89% 89%
-
-0.01 -0.01
89% 89%
-
- Selling and administrative expenses 4.95 4.95
5% 5%
-
- Research and development costs 5.64 5.64
26% 26%
-
-11 -11
8% 8%
-
- Depreciation and amortization 0.01 0.01
89% 89%
-
EBIT (operating result) EBIT -11 -11
7% 7%
-
Net profit -10 -10
4% 4%
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the Tenax Therapeutics, Inc. share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Tenax Therapeutics, Inc. Share News

Neutral
GlobeNewsWire
about 2 months ago
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan for  Treatment of PH-HFpEF Expanded Intellectual Property Estate for Levosimendan with Issuance of New U.S. Patent Recently Hosted KOL Event, “LEVEL Setting,” Featuring Four Experts in Heart Failure Discussing the Unmet Medical Need in PH-HFp...
Neutral
GlobeNewsWire
2 months ago
CHAPEL HILL, N.C., April 30, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a pate...
Neutral
GlobeNewsWire
3 months ago
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role for levosimendan in treating this prevalent, fatal disease
More Tenax Therapeutics, Inc. News

Company profile

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Head office United States
CEO Christopher Giordano
Employees 5
Founded 1967
Website www.tenaxthera.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now